# Recombinant Human LIGHT/TNFSF14 Protein(Fc Tag)

Catalog Number: PDMH100322



Note: Centrifuge before opening to ensure complete recovery of vial contents.

-					
- 1	00	cri	m	17	٦m
J			174	, T. U	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

Species Human

Source Mammalian-derived Human LIGHT/TNFSF14 proteins Ile84-Val240, with an C-terminal

Fc

 Mol\_Mass
 42.2 kDa

 Accession
 O43557

**Bio-activity** Not validated for activity

### **Properties**

**Purity** > 90% as determined by reducing SDS-PAGE.

**Endotoxin** < 1.0 EU/mg of the protein as determined by the LAL method

**Storage** Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

Shipping

This product is provided as lyophilized powder which is shipped with ice packs.

Formulation


Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5%

Mannitol.

**Reconstitution** It is recommended that sterile water be added to the vial to prepare a stock solution of

0.5 mg/mL. Concentration is measured by UV-Vis.

### Data



SDS-PAGE analysis of Human LIGHT/TNFSF14 proteins ,  $2\mu g/lane \ of \ Recombinant \ Human \ LIGHT/TNFSF14 \ proteins$  was resolved with SDS-PAGE under reducing conditions , showing bands at 45 KD

## Background

### For Research Use Only

# Recombinant Human LIGHT/TNFSF14 Protein(Fc Tag)

Catalog Number: PDMH100322



LIGHT , also known as TNFSF14 or CD258 , is a newly identified member of the TNF superfamily (TNFSF14) that is expressed by activated T lymphocytes , monocytes , granulocytes , spleen cells , and immature dendritic cells. TNFSF14 / LIGHT / CD258 is a type II transmembrane protein that is known to bind 2 membrane-bound TNFSF signaling receptor s: HVEM , which is predominantly expressed by T cells , and lymphotoxin  $\beta$  receptor (LT $\beta$ R) , which is expressed by stromal cells and nonlymphoid hematopoietic cells. TNFSF14 / LIGHT / CD258 also binds to a soluble non-signaling receptor , decoy receptor 3 (DcR3) , which can modulate the function of LIGHT in vivo. TNFSF14 / LIGHT / CD258 can also costimulate T cell responses via HVEM , which is constitutively expressed in most lymphocyte subpopulations , including CD4+ and CD8+ T cells. In addition , TNFSF14 / LIGHT / CD258 has been shown to suppress tumor formation in vivo and to induce tumor cell apoptosis via the up-regulation of intercellular adhesion molecule 1 and an increased lymphocyte adhesion to cancer cells. Thus , TNFSF14 / LIGHT / CD258 is being actively investigated as a possible basis for cancer treatment.